7-Jan-2026
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Tue, 6-Jan 4:15 PM ET)
PRNewswire (Mon, 15-Dec 7:00 AM ET)
Anaptys Announces Participation in December Investor Conferences
Globe Newswire (Tue, 25-Nov 4:15 PM ET)
AnaptysBio’s $100 Million Stock Repurchase Plan Underscores Strong Cash Position and Strategic Shift
Market Chameleon (Fri, 21-Nov 3:56 AM ET)
Anaptys Announces $100 Million Stock Repurchase Plan
Globe Newswire (Fri, 21-Nov 4:00 AM ET)
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
Globe Newswire (Fri, 21-Nov 3:50 AM ET)
Globe Newswire (Mon, 10-Nov 9:00 AM ET)
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
Globe Newswire (Tue, 4-Nov 4:15 PM ET)
Anaptys Announces Participation in November Investor Conferences
Globe Newswire (Tue, 4-Nov 4:15 PM ET)
Globe Newswire (Wed, 29-Oct 9:15 AM ET)
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Anaptysbio trades on the NASDAQ stock market under the symbol ANAB.
As of January 7, 2026, ANAB stock price climbed to $45.21 with 634,397 million shares trading.
ANAB has a beta of 0.34, meaning it tends to be less sensitive to market movements. ANAB has a correlation of 0.01 to the broad based SPY ETF.
ANAB has a market cap of $1.26 billion. This is considered a Small Cap stock.
Last quarter Anaptysbio reported $76 million in Revenue and $.52 earnings per share. This beat revenue expectation by $51 million and exceeded earnings estimates by $1.69.
In the last 3 years, ANAB traded as high as $52.47 and as low as $12.21.
The top ETF exchange traded funds that ANAB belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.
ANAB has outperformed the market in the last year with a return of +204.9%, while the SPY ETF gained +18.4%. In the last 3 month period, ANAB beat the market returning +51.4%, while SPY returned +3.4%. However, in the most recent 2 weeks ANAB has underperformed the stock market by returning -9.6%, while SPY returned -0.1%.
ANAB support price is $42.40 and resistance is $45.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANAB shares will trade within this expected range on the day.